Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Samsung Biologics Co.,Ltd. (207940.KS)
KRW1,368,000.00
-32,000.00 (-2.29%)
KR KSC Healthcare Biotechnology
Address
300, Songdo Bio-daero 21987
Incheon, KR
Incheon, KR
CEO
John Chongbo Rim
Website
samsungbiologics.com
IPO
2016-11-11
ISIN KR7207940008
Description
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW1,368,000.00
-32,000.00 (-2.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
62.9K
Beta
0.20
Float Shares
11.84M
Free Float %
25.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.73% | -4.75% | -7.28% | -23.34% | -15.18% | -19.01% | -14.10% | +13.94% | +4.91% | +448.91% | +448.91% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,368,000.00
DCF (Levered)
2,298,978.56
+68.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 11 | +2 |
| Buy | 15 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
11.38
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✓ MOAT relativo
★ Strong MOAT
-
Revenue growth Biotechnology: +1.6%+30.3% ★ Q1'26: -3.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+64.9% ★ Q1'26: +25.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+30.8% ★ Q1'26: +54.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+45.4% ★ Q1'26: +46.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+22.8% ★ Q1'26: +22.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.34× ★ Q1'26: 0.44× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 18 Rev. Ana. 15 EPS Ana. |
Dec 2027 19 Rev. Ana. 17 EPS Ana. |
Dec 2028 8 Rev. Ana. 10 EPS Ana. |
Dec 2029 10 Rev. Ana. 13 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
294.62B
est: 294.75B (0.0%)
|
464.63B
est: 456.09B (+1.9%)
|
535.81B
est: 527.80B (+1.5%)
|
701.59B
est: 695.17B (+0.9%)
|
1.16T
est: 1.07T (+8.7%)
|
1.57T
est: 1.54T (+1.5%)
|
3.00T
est: 2.84T (+5.6%)
|
3.69T
est: 3.68T (+0.4%)
|
3.50T
est: 4.52T (-22.7%)
|
4.56T
est: 5.73T (-20.4%)
|
5.41T
5.34T – 5.48T
-5.6% YoY
|
6.19T
5.70T – 7.69T
+14.5% YoY
|
6.92T
6.58T – 7.84T
+11.7% YoY
|
7.84T
7.46T – 8.89T
+13.3% YoY
|
| EBITDA |
29.73B
est: 129.37B (-77.0%)
|
135.91B
est: 200.19B (-32.1%)
|
147.13B
est: 231.66B (-36.5%)
|
224.63B
est: 305.12B (-26.4%)
|
436.47B
est: 470.16B (-7.2%)
|
699.10B
est: 678.12B (+3.1%)
|
1.29T
est: 1.25T (+3.5%)
|
1.60T
est: 1.62T (-0.7%)
|
1.92T
est: 2.22T (-13.4%)
|
2.70T
est: 2.81T (-3.8%)
|
2.65T
2.62T – 2.69T
-5.6% YoY
|
3.04T
2.79T – 3.77T
+14.5% YoY
|
3.39T
3.23T – 3.85T
+11.7% YoY
|
3.84T
3.66T – 4.36T
+13.3% YoY
|
| EBIT |
-30.42B
est: 94.41B (-132.2%)
|
65.98B
est: 146.08B (-54.8%)
|
55.68B
est: 169.05B (-67.1%)
|
92.08B
est: 222.66B (-58.6%)
|
293.30B
est: 343.09B (-14.5%)
|
537.31B
est: 494.84B (+8.6%)
|
983.63B
est: 910.53B (+8.0%)
|
1.11T
est: 1.18T (-5.5%)
|
1.32T
est: 1.63T (-19.0%)
|
2.07T
est: 2.07T (+0.2%)
|
1.95T
1.92T – 1.98T
-5.6% YoY
|
2.23T
2.06T – 2.77T
+14.5% YoY
|
2.50T
2.37T – 2.83T
+11.7% YoY
|
2.83T
2.69T – 3.21T
+13.3% YoY
|
| Net Income |
-176.82B
est: -198.66B (+11.0%)
|
-96.97B
est: -99.60B (+2.6%)
|
224.11B
est: 279.31B (-19.8%)
|
202.90B
est: 197.00B (+3.0%)
|
240.97B
est: 229.95B (+4.8%)
|
393.59B
est: 440.82B (-10.7%)
|
798.06B
est: 603.40B (+32.3%)
|
857.69B
est: 793.07B (+8.1%)
|
1.08T
est: 961.93B (+12.6%)
|
1.78T
est: 1.46T (+22.0%)
|
1.88T
1.87T – 1.90T
+28.8% YoY
|
2.21T
2.04T – 2.49T
+17.4% YoY
|
2.47T
2.31T – 2.90T
+11.6% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
49.68B
est: 25.94B (+91.5%)
|
55.33B
est: 40.14B (+37.8%)
|
73.30B
est: 46.45B (+57.8%)
|
88.28B
est: 61.18B (+44.3%)
|
106.08B
est: 94.27B (+12.5%)
|
169.90B
est: 135.97B (+25.0%)
|
290.31B
est: 250.19B (+16.0%)
|
565.19B
est: 323.88B (+74.5%)
|
318.80B
est: 480.23B (-33.6%)
|
372.25B
est: 607.98B (-38.8%)
|
574.15B
566.53B – 581.69B
-5.6% YoY
|
657.44B
604.89B – 816.57B
+14.5% YoY
|
734.41B
698.81B – 832.82B
+11.7% YoY
|
832.04B
791.71B – 943.53B
+13.3% YoY
|
| EPS |
-4,739.12
est: -4,291.89 (-10.4%)
|
-2,230.35
est: -2,151.74 (-3.7%)
|
5,152.93
est: 6,034.21 (-14.6%)
|
4,665.54
est: 4,256.02 (+9.6%)
|
5,540.93
est: 4,967.81 (+11.5%)
|
9,050.12
est: 9,523.28 (-5.0%)
|
17,592.00
est: 13,035.78 (+35.0%)
|
18,528.00
est: 17,133.19 (+8.1%)
|
23,402.00
est: 20,802.98 (+12.5%)
|
38,588.00
est: 31,620.93 (+22.0%)
|
40,720.55
40,440.78 – 41,188.85
+28.8% YoY
|
47,795.71
44,103.90 – 53,821.90
+17.4% YoY
|
53,358.22
49,996.06 – 62,653.43
+11.6% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
915.40B
OE per share TTM
19,754.97
Owner's Yield
1.45%
Maintenance CapEx ratio
30.61%
Maint CapEx / Avg PPE
142.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
433.80M
Shares Outstanding
46.29M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Chongbo Rim | Chief Executive Officer, President & Chairman of Board | 8B | male |
| Kun Lo | Executive Vice President, Head of EPCV Center & Director | 2B | — |
| James J. Choi | Executive Vice President, Head of CDO Development Center & Head of Sales Center | 569M | male |
| Kyuho Lee | Executive Vice President, Head of People Center, & Chief Human Resource Officer | — | male |
| Pierre Catignol | Executive Vice President & Head of Operation Center | — | male |
| Seungho Ryu | EVP, CFO, Head of Business Support Center & Director | — | male |
| Heejeong Kim | VP & Head of DS Department | — | female |
| Sojeong Lee | Vice President & Head of Regulatory Affairs | — | — |
| Heekyun Lim | Vice President & Head of Business Consulting Team | — | male |
| Kevin Sharp | EVP, Head of Sales & Operations Department | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 207940.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
